11 Oct 2017 07:00
11 October 2017
AIM: AMYT
ESM: AYP
Amryt Pharma plc
("Amryt" or the "Company")
Director share purchases
Amryt, the biopharmaceutical company focused on rare and orphan diseases, is pleased to announce that, following approval of the Placing, it has received notification that Harry Stratford, Non-Executive Chairman, Joe Wiley, Chief Executive Officer, Rory Nealon, Chief Financial Officer and Chief Operating Officer, Markus Ziener and James Culverwell, Non-Executive Directors of the Company, acquired, in aggregate, 947,731 ordinary shares of 1p each ("Ordinary Shares"). The details of the purchases are as follows:
1. | Details of the person discharging managerial responsibilities / person closely associated | ||||
a) | Name | Harry Stratford | |||
2. | Reason for the notification | ||||
a) | Position / status | Non-Executive Chairman | |||
b) | Initial notification / amendment | Initial notification | |||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | Amryt Pharma plc | |||
b) | Legal entity identifier | 213800BOS8WAJO2BEQ38 | |||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a) | Description of the financial instrument, type of instrument | Ordinary shares of £0.01 each | |||
Identification code | GB00BDD1LS57 | ||||
b) | Nature of the transaction | Purchase of ordinary shares as part of placing announced on 21 September 2017 | |||
c) | Currency | British Pounds | |||
d) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£0.20 | 150,000 | ||||
e) | Aggregated information · Aggregated volume · Aggregated price |
150,000 £30,000 | |||
f) | Date of the transaction | 11 October 2017 | |||
g) | Place of the transaction | London Stock Exchange, AIM | |||
1. | Details of the person discharging managerial responsibilities / person closely associated | ||||
a) | Name | Joe Wiley | |||
2. | Reason for the notification | ||||
a) | Position / status | Director | |||
b) | Initial notification / amendment | Initial notification | |||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | Amryt Pharma plc | |||
b) | Legal entity identifier | 213800BOS8WAJO2BEQ38 | |||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a) | Description of the financial instrument, type of instrument | Ordinary shares of £0.01 each | |||
Identification code | GB00BDD1LS57 | ||||
b) | Nature of the transaction | Purchase of ordinary shares as part of placing announced on 21 September 2017 | |||
c) | Currency | British Pounds | |||
d) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£0.20 | 221,592 | ||||
e) | Aggregated information · Aggregated volume · Aggregated price |
221,592 £44,318.40 | |||
f) | Date of the transaction | 11 October 2017 | |||
g) | Place of the transaction | London Stock Exchange, AIM | |||
1. | Details of the person discharging managerial responsibilities / person closely associated | ||||
a) | Name | Rory Nealon | |||
2. | Reason for the notification | ||||
a) | Position / status | Director | |||
b) | Initial notification / amendment | Initial notification | |||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | Amryt Pharma plc | |||
b) | Legal entity identifier | 213800BOS8WAJO2BEQ38 | |||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a) | Description of the financial instrument, type of instrument | Ordinary shares of £0.01 each | |||
Identification code | GB00BDD1LS57 | ||||
b) | Nature of the transaction | Purchase of ordinary shares as part of placing announced on 21 September 2017 | |||
c) | Currency | British Pounds | |||
d) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£0.20 | 221,592 | ||||
e) | Aggregated information · Aggregated volume · Aggregated price |
221,592 £44,318.40 | |||
f) | Date of the transaction | 11 October 2017 | |||
g) | Place of the transaction | London Stock Exchange, AIM | |||
1. | Details of the person discharging managerial responsibilities / person closely associated | ||||
a) | Name | James Culverwell | |||
2. | Reason for the notification | ||||
a) | Position / status | Non-Executive Director | |||
b) | Initial notification / amendment | Initial notification | |||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | Amryt Pharma plc | |||
b) | Legal entity identifier | 213800BOS8WAJO2BEQ38 | |||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a) | Description of the financial instrument, type of instrument | Ordinary shares of £0.01 each | |||
Identification code | GB00BDD1LS57 | ||||
b) | Nature of the transaction | Purchase of ordinary shares as part of placing announced on 21 September 2017 | |||
c) | Currency | British Pounds | |||
d) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£0.20 | 221,592 | ||||
e) | Aggregated information · Aggregated volume · Aggregated price |
221,592 £44,318.40 | |||
f) | Date of the transaction | 11 October 2017 | |||
g) | Place of the transaction | London Stock Exchange, AIM | |||
1. | Details of the person discharging managerial responsibilities / person closely associated | ||||
a) | Name | Marcus Ziener | |||
2. | Reason for the notification | ||||
a) | Position / status | Non-Executive Director | |||
b) | Initial notification / amendment | Initial notification | |||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | Amryt Pharma plc | |||
b) | Legal entity identifier | 213800BOS8WAJO2BEQ38 | |||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a) | Description of the financial instrument, type of instrument | Ordinary shares of £0.01 each | |||
Identification code | GB00BDD1LS57 | ||||
b) | Nature of the transaction | Purchase of ordinary shares as part of placing announced on 21 September 2017 | |||
c) | Currency | British Pounds | |||
d) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£0.20 | 132,955 | ||||
e) | Aggregated information · Aggregated volume · Aggregated price |
132,955 £26,591 | |||
f) | Date of the transaction | 11 October 2017 | |||
g) | Place of the transaction | London Stock Exchange, AIM | |||
Enquiries:
Amryt Pharma plc | C/o KTZ Communications (details below) |
Joe Wiley, CEO Rory Nealon, CFO/COO | |
Shore Capital | +44 (0) 20 7408 4090 |
Nomad, Joint Bookrunner and Joint Broker | |
Edward Mansfield, Mark Percy
| |
WG Partners | +44 (0) 20 3705 9321 |
Joint Bookrunner | |
Nigel Barnes, Nigel Birks, Chris Lee
| |
Davy | +353 (1) 679 6363 |
ESM Adviser and Joint Broker | |
John Frain, Anthony Farrell
| |
Stifel | +44 (0) 20 7710 7600 |
Joint Broker | |
Jonathan Senior, Ben Maddison
| |
KTZ Communications | +44 (0) 20 3178 6378 |
Katie Tzouliadis, Irene Bermont-Penn, Emma Pearson |